Wedbush Increases Earnings Estimates for Solid Biosciences

Solid Biosciences Inc. (NASDAQ:SLDB) – Wedbush lifted their Q1 2025 earnings per share estimates for Solid Biosciences in a note issued to investors on Wednesday, February 19th. Wedbush analyst L. Chico now anticipates that the company will post earnings per share of ($0.60) for the quarter, up from their prior estimate of ($0.77). Wedbush has a “Strong-Buy” rating on the stock. The consensus estimate for Solid Biosciences’ current full-year earnings is ($2.84) per share. Wedbush also issued estimates for Solid Biosciences’ Q2 2025 earnings at ($0.43) EPS, Q3 2025 earnings at ($0.45) EPS, Q4 2025 earnings at ($0.46) EPS, FY2025 earnings at ($1.90) EPS, FY2026 earnings at ($1.78) EPS, FY2027 earnings at ($1.79) EPS, FY2028 earnings at ($1.41) EPS and FY2029 earnings at ($0.55) EPS.

Other equities research analysts have also issued research reports about the company. JPMorgan Chase & Co. dropped their price target on Solid Biosciences from $15.00 to $12.00 and set an “overweight” rating on the stock in a research report on Tuesday, November 12th. HC Wainwright reaffirmed a “buy” rating and set a $16.00 price target on shares of Solid Biosciences in a research report on Friday, January 10th. Citizens Jmp raised Solid Biosciences to a “strong-buy” rating in a research report on Tuesday, December 10th. JMP Securities assumed coverage on Solid Biosciences in a research report on Tuesday, December 10th. They set an “outperform” rating and a $15.00 price target on the stock. Finally, Truist Financial assumed coverage on Solid Biosciences in a research report on Wednesday, January 8th. They set a “buy” rating and a $16.00 price target on the stock. Nine analysts have rated the stock with a buy rating and four have given a strong buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Buy” and an average price target of $15.40.

Solid Biosciences Stock Performance

Shares of SLDB opened at $6.00 on Friday. Solid Biosciences has a 1 year low of $2.88 and a 1 year high of $15.05. The stock’s 50-day moving average price is $3.81 and its two-hundred day moving average price is $5.78.

Insider Buying and Selling at Solid Biosciences

In other Solid Biosciences news, CEO Alexander Cumbo sold 11,114 shares of the firm’s stock in a transaction that occurred on Tuesday, December 3rd. The stock was sold at an average price of $5.60, for a total value of $62,238.40. Following the completion of the transaction, the chief executive officer now directly owns 38,484 shares in the company, valued at $215,510.40. This trade represents a 22.41 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Jessie Hanrahan sold 4,610 shares of the firm’s stock in a transaction that occurred on Tuesday, December 3rd. The shares were sold at an average price of $5.60, for a total value of $25,816.00. Following the completion of the transaction, the insider now owns 14,235 shares of the company’s stock, valued at approximately $79,716. This represents a 24.46 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 26,069 shares of company stock worth $137,301 over the last ninety days. 13.63% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Wells Fargo & Company MN boosted its stake in shares of Solid Biosciences by 29.4% during the 4th quarter. Wells Fargo & Company MN now owns 13,138 shares of the company’s stock worth $53,000 after acquiring an additional 2,986 shares during the period. Rhumbline Advisers boosted its stake in shares of Solid Biosciences by 10.5% during the 4th quarter. Rhumbline Advisers now owns 43,677 shares of the company’s stock worth $175,000 after acquiring an additional 4,161 shares during the period. Wellington Management Group LLP boosted its stake in shares of Solid Biosciences by 4.0% during the 4th quarter. Wellington Management Group LLP now owns 124,551 shares of the company’s stock worth $498,000 after acquiring an additional 4,747 shares during the period. Geode Capital Management LLC boosted its stake in shares of Solid Biosciences by 1.0% during the 4th quarter. Geode Capital Management LLC now owns 509,802 shares of the company’s stock worth $2,040,000 after acquiring an additional 4,932 shares during the period. Finally, American Century Companies Inc. boosted its stake in shares of Solid Biosciences by 12.3% during the 4th quarter. American Century Companies Inc. now owns 46,857 shares of the company’s stock worth $187,000 after acquiring an additional 5,126 shares during the period. 81.46% of the stock is currently owned by institutional investors.

About Solid Biosciences

Solid Biosciences Inc, a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia.